Lumos Pharma to Participate in March 2021 Investor Conferences
AUSTIN, Texas, March 11, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO) announces participation in several virtual investor conferences in March 2021. Highlights include:
- H.C. Wainwright Global Life Sciences Conference on March 10, 2021 with a pre-recorded presentation.
- Oppenheimer 31st Annual Healthcare Conference on March 17, 2021 with a live presentation and one-on-one meetings.
- 33rd Annual Roth Conference on March 15-17, 2021 featuring presentations and meetings.
Lumos Pharma focuses on developing therapeutics for rare diseases and is evaluating LUM-201 for Pediatric Growth Hormone Deficiency.
- None.
- None.
AUSTIN, Texas, March 11, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company is participating in the following March 2021 virtual investor conferences:
H.C. Wainwright Global Life Sciences Conference
- March 10, 2021 – Pre-recorded presentation available for download
Oppenheimer 31st Annual Healthcare Conference
- March 17, 2021 – Presentation 9:20 – 9:50 AM ET
- March 17, 2021 – One-on-One Meetings throughout the day
33rd Annual Roth Conference
- March 15, 2021 – One-on-One Meetings throughout the day
- March 17, 2021 – Presentation 10:00 – 10:25 AM ET
Inaugural Emerging Growth Conference presented by M-Vest LLC and Maxim Group LLC
- March 17-19, 2021 – Pre-recorded presentation available 9:00 AM - 5:00 PM ET on M-Vest platform
- March 23, 2021 – Pre-recorded presentation available at 9:00 AM ET on Lumos Pharma’s website
Live Lumos Pharma presentations, as well as those available for download, can be found on the Company’s website under “Events & Presentations” in the Investors & Media section. Please contact your institutional salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team during these conferences or thereafter.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2b clinical trial, the OraGrowtH210 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
FAQ
When is Lumos Pharma participating in the H.C. Wainwright Global Life Sciences Conference?
What are the dates for the Oppenheimer 31st Annual Healthcare Conference for Lumos Pharma?
Is Lumos Pharma presenting at the Roth Conference in March 2021?
When can I access Lumos Pharma's presentations from the Emerging Growth Conference?
What is Lumos Pharma's lead therapeutic candidate?
